Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) EPS (Basic) (2017 - 2024)

Solid Biosciences (SLDB) has disclosed EPS (Basic) for 8 consecutive years, with -$1.02 as the latest value for Q4 2024.

  • Quarterly EPS (Basic) fell 2.0% to -$1.02 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$3.06 through Dec 2024, up 36.78% year-over-year, with the annual reading at -$1.99 for FY2025, 34.97% up from the prior year.
  • EPS (Basic) hit -$1.02 in Q4 2024 for Solid Biosciences, down from -$0.79 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.17 in Q2 2021 to a low of -$24.11 in Q4 2020.
  • Historically, EPS (Basic) has averaged -$2.44 across 5 years, with a median of -$1.01 in 2023.
  • Biggest five-year swings in EPS (Basic): plummeted 3498.51% in 2020 and later skyrocketed 89.8% in 2021.
  • Year by year, EPS (Basic) stood at -$24.11 in 2020, then surged by 89.8% to -$2.46 in 2021, then skyrocketed by 72.36% to -$0.68 in 2022, then plummeted by 47.06% to -$1.0 in 2023, then fell by 2.0% to -$1.02 in 2024.
  • Business Quant data shows EPS (Basic) for SLDB at -$1.02 in Q4 2024, -$0.79 in Q3 2024, and -$0.61 in Q2 2024.